Join Growin Stock Community!

Arvinas, inc.ARVN.US Overview

US StockHealthcare
(No presentation for ARVN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ARVN AI Insights

ARVN Overall Performance

ARVN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ARVN Recent Performance

-2.41%

Arvinas, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ARVN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ARVN Key Information

ARVN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ARVN Profile

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Price of ARVN

ARVN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ARVN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.10
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.71
PB Ratio
1.52
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-30.77%
Revenue Growth (YoY)
-0.30%
Profit Growth (YoY)
-0.30%
3-Year Revenue Growth
11.41%
3-Year Profit Growth
11.41%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.10
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.71
PB Ratio
1.52
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-30.77%
Revenue Growth (YoY)
-0.30%
Profit Growth (YoY)
-0.30%
3-Year Revenue Growth
11.41%
3-Year Profit Growth
11.41%
  • When is ARVN's latest earnings report released?

    The most recent financial report for Arvinas, inc. (ARVN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ARVN's short-term business performance and financial health. For the latest updates on ARVN's earnings releases, visit this page regularly.

  • What is the operating profit of ARVN?

    According to the latest financial report, Arvinas, inc. (ARVN) reported an Operating Profit of -74.6M with an Operating Margin of -785.26% this period, representing a decline of 28.18% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ARVN's revenue growth?

    In the latest financial report, Arvinas, inc. (ARVN) announced revenue of 9.5M, with a Year-Over-Year growth rate of -83.95%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ARVN have?

    As of the end of the reporting period, Arvinas, inc. (ARVN) had total debt of 8.9M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ARVN have?

    At the end of the period, Arvinas, inc. (ARVN) held Total Cash and Cash Equivalents of 142.9M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ARVN go with three margins increasing?

    In the latest report, Arvinas, inc. (ARVN) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -785.26%%, and net margin of -709.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ARVN's profit trajectory and future growth potential.

  • Is ARVN's EPS continuing to grow?

    According to the past four quarterly reports, Arvinas, inc. (ARVN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.96. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ARVN?

    Arvinas, inc. (ARVN)'s Free Cash Flow (FCF) for the period is -30.6M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 63.74% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ARVN?

    The latest valuation data shows Arvinas, inc. (ARVN) has a Price-To-Earnings (PE) ratio of -9.79 and a Price/Earnings-To-Growth (PEG) ratio of -0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.